Auspex Announces Favorable Topline Results From Thorough QT

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auspex Announces Favorable Topline Results From Thorough QT Clinical Trial of SD-809

SD-809 Met Primary Outcome Measure, Showed No Clinically Significant QT Prolongation

NDA Submission Planned by Mid-2015

LA JOLLA, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX ), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced favorable topline safety results from its thorough QT (TQT) clinical trial evaluating the effects of SD-809 on cardiac repolarization, based on placebo-corrected, time-matched changes from baseline in the corrected QT (QTc) interval. The TQT clinical trial demonstrated that at two different dose levels, SD-809 had no clinically significant effect on cardiac repolarization as assessed by the QT interval. A tetrabenazine arm was included for comparison and demonstrated an increase in QTc that is consistent with the effect reported in the FDA label for Xenazine ® . The clinical trial's assay sensitivity was established by the observation of characteristic QTc prolongation following dosing with moxifloxacin.

"We are very pleased with the results of this TQT study," said Pratik Shah, Ph.D., president and chief executive officer of Auspex Pharmaceuticals. "This study is another important step forward in our path to advance SD-809 to market and bring this much-needed therapy to patients living with serious movement disorders."

Thorough QT Topline Results

The key outcome measure in this active- and placebo-controlled crossover study was to determine the effect of single doses of SD-809 on the QTc interval. Assay sensitivity was established with a moxifloxacin arm, and a tetrabenazine arm was also included for comparison. A 50 mg dose of tetrabenazine was selected as this was the maximal dose employed in the TQT study for Xenazine that led to the warning and precaution in the product label. A 24 mg dose of SD-809 was selected as it provides comparable systemic exposure (AUC) to 50 mg of tetrabenazine, but with a lower peak concentration (Cmax). For SD-809, a 12 mg dose led to a maximal increase in the QTc of approximately 0.8 msec and a 24 mg dose led to maximal increase in the QTc of approximately 2.6 msec. The placebo-corrected time-matched maximal increases in QTc for the 12 and 24 mg doses of SD-809 were 2.8 msec (90% two-sided Confidence Interval (CI): 0.7 to 4.8) and 4.5 msec (90% two-sided CI: 2.4 to 6.5), respectively. A 50 mg dose of tetrabenazine led to a maximal increase in QTc of approximately 7.2 msec, with a placebo-corrected time-matched maximal increase in QTc of 7.6 msec (90% two-sided CI: 5.6 to 9.5).

A summary of the outcome measures from the TQT clinical trial are as follows:

 
  SD-809
(12 mg)
SD-809
(24 mg)
Tetrabenazine
(50 mg)
Moxifloxacin
Positive Control

(400 mg)
Maximal mean change from baseline in QTc (msec) 0.8 2.6 7.2 10.2
Placebo-corrected, time-matched maximal mean change from baseline in QTc (msec) 2.8 4.5 7.6 14.0

  About the TQT Study

The Phase 1 TQT study was conducted in 48 healthy volunteers. This was a single-center, randomized, double-blind, placebo- and positive-controlled six-period crossover study to evaluate the effects of low-dose (12 mg) and high-dose (24 mg) SD-809 on cardiac repolarization, based on placebo-corrected, time-matched changes from baseline in the QTcF interval. Assay sensitivity was established by using moxifloxacin as the positive control. In addition, the effects of tetrabenazine on cardiac repolarization (also based on placebo-corrected, time-matched changes from baseline in the QTc interval) were evaluated in this study.

Relevance of QT/QTc Interval Prolongation from ICH Guidance

Drugs that prolong the mean QT/QTc interval by around 5 msec or less do not appear to cause torsades de pointes or TdP, a type of cardiac arrhythmia. Whether this signifies that no increased risk of cardiac arrhythmia exists for these compounds or simply that the increased risk has been too small to detect is not clear. The data on drugs that prolong the mean QT/QTc interval by more than around 5 msec and less than 20 msec are inconclusive, but some of these compounds have been associated with proarrhythmic risk. Drugs that prolong the mean QT/QTc interval by >20 msec have a substantially increased likelihood of being proarrhythmic, and might have clinical arrhythmic events captured during drug development.

The threshold level of regulatory concern is around 5 msec, as evidenced by an upper bound of the 95% confidence interval (CI) around the mean effect on QTc of 10 msec. Note that the upper limit of the 95% one-sided CI is equivalent to the upper limit of the 90% two-sided CI.

Outlook

In December 2014, Auspex reported positive topline results from a Phase 3 clinical trial evaluating SD-809 in chorea associated with Huntington's disease, demonstrating robust efficacy, supported by significant improvements in patient global impression of change, clinical global impression of change and quality of life as well as a favorable safety and tolerability profile.

Based on these positive SD-809 data, Auspex is providing one-time guidance regarding its planned spending in 2015. Auspex intends to incur $85-$90 million in research and development (R&D) expense and $25-$30 million in general and administrative (G&A) expense in 2015. These two ranges include $14 million of non-cash stock-based compensation expense. 

The increase in R&D costs from 2014 is driven by expanded pipeline costs, increased costs for regulatory activities in preparation for SD-809's anticipated NDA submission and increased medical affairs and pre-commercial manufacturing costs in preparation for the potential commercial launch of SD-809 for chorea associated with Huntington's disease. The increase in G&A expense from 2014 is primarily driven by preparation for the potential commercial launch of SD-809 for chorea associated with Huntington's disease.

About Auspex Pharmaceuticals

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven pharmacologics. The company's lead product SD-809 is in the final stages of development for the treatment of chorea associated with Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behavior and movements. In addition, Auspex is investing in the broad potential of SD-809 for the treatment of other movement disorders, including tardive dyskinesia and tics associated with Tourette syndrome. The company's pipeline also includes SD-560, which is being developed for fibrotic conditions. For further information, please visit the company's website www.auspexpharma.com .

Forward-Looking Statements

Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Auspex's ability to successfully complete its ongoing clinical trials and development programs, Auspex's ability to obtain regulatory approval for its product candidates and market penetration and acceptance of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: Auspex's future preclinical studies and clinical trials may not be successful; changes in regulatory requirements in the United States and foreign countries may prevent or significantly delay regulatory approval of Auspex's product candidates; Auspex may change its plans to develop and commercialize its product candidates; the U.S. Food and Drug Administration (FDA) may not agree with Auspex's interpretation of the data from clinical trials of its product candidates, including the TQT clinical trial; Auspex may decide, or the FDA may require Auspex, to conduct additional clinical trials or to modify Auspex's ongoing clinical trials; Auspex may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Auspex's ability to obtain regulatory approval; the third parties with whom Auspex has partnered for the development of its product candidates and upon whom Auspex relies to conduct its clinical trials and manufacture its product candidates may not perform as expected; Auspex's product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of Auspex's product candidates could delay or prevent regulatory approval or commercialization; Auspex may be unable to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; Auspex's ability to obtain additional financing; and the accuracy of Auspex's estimates regarding expenses, future revenues and capital requirements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Other risks and uncertainties affecting Auspex are described more fully in Auspex's filings with the Securities and Exchange Commission. Auspex undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Corporate Communications Contacts: For Media: Dan Budwick, Pure Communications, Inc. (973) 271-6085 For Investors: Monique Allaire Lyons, Pure Communications, Inc. (617) 895-9511

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 101

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 58

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 113

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 43

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 124

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Coop Pank Reveals Q3 2025 Financial Results During Webinar

Updated Category News Views 161

Insights from Coop Pank's Recent Investor Webinar Coop Pank recently held an engaging investor webinar to discuss their unaudited financial results for the third quarter of 2025. During this informative session, Arko Kurtmann, the Chairman of the Management Board, and Paavo Truu, the Chief Financial Officer, elaborated on the bank's performance, highlighting significant...

Continue Reading
inTEST EMS Expands Market Reach Through New Distributor

Updated Category News Views 261

inTEST EMS Partners with General Bussan Co., Ltd. inTEST Electronic Test, part of inTEST Corporation (NYSE American: INTT), has announced a significant strategic partnership with General Bussan Co., Ltd. This collaboration is aimed at enhancing the distribution of inTEST EMS Products' high-quality manipulators, interface solutions, and docking systems designed...

Continue Reading
Gordon Brothers List Union Electric Steel Plant for Sale

Updated Category News Views 230

Gordon Brothers List Union Electric Steel Plant for Sale In the recent announcement, Gordon Brothers, renowned experts in asset management, are presenting a noteworthy opportunity for interested buyers. The entire roll manufacturing facility of Union Electric Steel Limited is now available for private sale, conducted by joint administrators. This facility is located in...

Continue Reading
AHLA Foundation's Summit Empowers Survivors and Experts

Updated Category News Views 157

Uniting Voices Against Human Trafficking The AHLA Foundation recently brought together a dynamic group of survivors, industry experts, and leaders at the No Room for Trafficking (NRFT) Summit. This significant event emphasized the importance of collaboration in the fight against human trafficking, focusing on education and the distribution of vital resources aimed at...

Continue Reading
Trump Media's Stock Reactions Amid Market Fluctuations Analysis

Updated Category News Views 158

Trump Media's Stock Takes a Hit Amid Insider Selling Concerns The shares of Trump Media have been quite turbulent lately, especially following reports that insiders within the company were given the green light to sell their holdings. This news is closely linked to former President Donald Trump, who has a significant stake in the company. Snapshot of Current Stock...

Continue Reading